Clinical Trial Update: A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 randomized, open-label trial comparing RRx-001 to regorafenib in metastatic colorectal cancer has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• RRx-001
• Stivarga (regorafenib)

Snippet

Sponsor: EpicentRx, Inc. | Conditions: Colorectal Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2024-10-15